Despite antimicrobial resistance being consistently ranked among the most urgent public health threats by the CDC and WHO, the pharmaceutical pipeline for genuinely novel antibiotics — particularly those effective against the most resistant, hardest-to-treat pathogens — has narrowed considerably compared to prior decades. The underlying cause is not a lack of scientific opportunity but a well-documented economic market failure specific to antibiotic development.
The Core Economic Problem
Unlike a chronic disease medication taken daily for years, a new antibiotic is typically used for a short course, often reserved specifically for resistant infections where other options have failed — and stewardship programs actively work to limit its use precisely to preserve effectiveness against future resistance. This creates a direct tension: the clinical and public health goal is to use a valuable new antibiotic sparingly, but sparse use generates limited revenue relative to the hundreds of millions of dollars typically required to bring a new antibiotic through clinical trials and regulatory approval — a mismatch that has driven many large pharmaceutical companies to exit antibiotic research and development entirely over the past two decades.
Several High-Profile Antibiotic Company Failures Illustrate the Problem
Multiple biotech companies that successfully developed and received FDA approval for genuinely novel antibiotics targeting resistant pathogens have subsequently filed for bankruptcy or been forced into distressed acquisition, despite bringing a clinically valuable drug to market — a pattern that has become a widely cited cautionary case study illustrating that scientific and regulatory success alone does not guarantee commercial viability in the current antibiotic market structure. These outcomes have had a chilling effect on further private investment in antibiotic-focused biotech.
Push Incentives Versus Pull Incentives
Policy responses to this market failure generally fall into two categories: "push" incentives, which reduce the cost of antibiotic development directly through grants and public funding for early-stage research (exemplified by programs like BARDA, the U.S. Biomedical Advanced Research and Development Authority), and "pull" incentives, which aim to guarantee a viable revenue stream for a successfully developed antibiotic independent of actual sales volume — recognizing that low-volume use, driven by appropriate stewardship, is a feature of good antibiotic policy rather than a bug to be solved through higher sales.
The Subscription Model Being Piloted
Several jurisdictions, including the United Kingdom's NHS, have piloted a "subscription" reimbursement model for novel antibiotics, paying a pharmaceutical manufacturer a fixed annual fee for access to a needed antibiotic regardless of how much of the drug is actually used — explicitly decoupling manufacturer revenue from prescription volume so that appropriate, stewardship-driven low usage does not undermine the drug's commercial viability. Similar subscription and delinkage models have been proposed and partially piloted in the United States, though full-scale adoption has moved more slowly than in the UK pilot.
The PASTEUR Act and Legislative Efforts
In the United States, legislative proposals including versions of the PASTEUR Act have aimed to establish a subscription-style model specifically for novel antibiotics targeting the most urgent resistant pathogens, guaranteeing government payment independent of volume in exchange for the manufacturer agreeing to appropriate stewardship-aligned marketing and distribution practices. These proposals have drawn bipartisan interest given the shared recognition of the underlying market failure, though enactment and funding have moved through multiple legislative cycles without full resolution.
Conclusion
The antibiotic development pipeline crisis is fundamentally an economic problem layered on top of a genuine scientific and clinical need — appropriately sparing use of a valuable new antibiotic directly undermines the commercial case for developing it under a traditional volume-based pharmaceutical revenue model. Subscription and delinkage-style reforms represent the most promising policy direction currently being tested, though full-scale implementation remains a work in progress. Facilities relying on the existing antibiotic supply depend on consistent pharmacy and lab supplies access to support accurate culture-guided prescribing.
